• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bigfoot buys connected insulin pen tech

June 8, 2017 By Sarah Faulkner

Bigfoot BiomedicalArtificial pancreas developer Bigfoot Biomedical said today that it acquired Patients Pending and its connected insulin pen technology for an undisclosed amount.

With this acquisition, Bigfoot said it is the 1st company to simultaneously pursue both insulin infusion and injection delivery solutions.

“Bigfoot isn’t in the pump business. And even though we are excited to add a connected dose capture technology for insulin injections, we aren’t in the pen business either. Bigfoot is a solutions company developing systems that connect components into Class III medical device systems capable of supporting auto-titration for insulin dosing across a variety of glucose sensing and insulin delivery technologies,” Jeffrey Brewer, president & CEO, said in prepared remarks. “We believe integrated systems are the future of diabetes therapy and, going forward, only systems will be able to compete to improve quality of life, lower clinical delivery costs, and decrease overall healthcare costs for people with insulin-requiring diabetes.”

Patients Pending founder, John Sjölund, plans to join Bigfoot Biomedical in connection with the acquisition. Sjölund has had Type I diabetes since he was 4 years old.

“To have the opportunity to work alongside this outstanding team, to make a real difference to those of us living with insulin-requiring diabetes, is going to be transformational,” Sjölund said. “I believe that the impact that Timesulin will have as a part of Bigfoot and the products we are going to bring for those on multiple daily injections will change the landscape forever.”

Bigfoot finished its 1st clinical trial late last year and is slated to a launch a pivotal trial for its automated insulin delivery system later this year.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Bigfoot Biomedical

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS